Whan In Pharm Co.,Ltd. (016580.KS)
KRW 11470.0
(0.61%)
KRW 11470.0
(0.61%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 66.41 Billion KRW | -1.49% |
| 2022 | 68.98 Billion KRW | 10.87% |
| 2021 | 62.21 Billion KRW | 6.93% |
| 2020 | 58.18 Billion KRW | 9.75% |
| 2019 | 53.01 Billion KRW | 2.04% |
| 2018 | 51.95 Billion KRW | 5.62% |
| 2017 | 49.19 Billion KRW | 3.15% |
| 2016 | 47.69 Billion KRW | 1.11% |
| 2015 | 47.16 Billion KRW | 12.72% |
| 2014 | 41.84 Billion KRW | 11.62% |
| 2013 | 37.48 Billion KRW | 5.34% |
| 2012 | 35.58 Billion KRW | -1.37% |
| 2011 | 36.08 Billion KRW | 3.42% |
| 2010 | 34.88 Billion KRW | 2.01% |
| 2009 | 34.2 Billion KRW | -0.01% |
| 2008 | 34.2 Billion KRW | 9.97% |
| 2007 | 31.1 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 62.82 Billion KRW | 1.5% |
| 2024 Q2 | 17.44 Billion KRW | 7.94% |
| 2024 Q1 | 16.15 Billion KRW | -5.51% |
| 2023 FY | 67.95 Billion KRW | -1.49% |
| 2023 Q1 | 16.53 Billion KRW | -4.57% |
| 2023 Q4 | 17.1 Billion KRW | -4.16% |
| 2023 Q3 | 17.84 Billion KRW | 3.41% |
| 2023 Q2 | 17.25 Billion KRW | 4.37% |
| 2022 Q2 | 17.78 Billion KRW | 15.45% |
| 2022 Q1 | 15.4 Billion KRW | -14.88% |
| 2022 Q4 | 17.32 Billion KRW | -6.23% |
| 2022 Q3 | 18.47 Billion KRW | 3.91% |
| 2022 FY | 68.98 Billion KRW | 10.87% |
| 2021 Q3 | 15.51 Billion KRW | 6.25% |
| 2021 FY | 62.21 Billion KRW | 6.93% |
| 2021 Q1 | 14.01 Billion KRW | -12.21% |
| 2021 Q2 | 14.6 Billion KRW | 4.21% |
| 2021 Q4 | 18.09 Billion KRW | 16.62% |
| 2020 Q3 | 13.59 Billion KRW | -4.82% |
| 2020 Q2 | 14.28 Billion KRW | -0.42% |
| 2020 FY | 58.18 Billion KRW | 9.75% |
| 2020 Q1 | 14.34 Billion KRW | 4.28% |
| 2020 Q4 | 15.95 Billion KRW | 17.39% |
| 2019 Q4 | 13.75 Billion KRW | 3.71% |
| 2019 Q2 | 13.62 Billion KRW | 10.11% |
| 2019 Q1 | 12.37 Billion KRW | -4.27% |
| 2019 FY | 53.01 Billion KRW | 2.04% |
| 2019 Q3 | 13.26 Billion KRW | -2.66% |
| 2018 Q1 | 12.81 Billion KRW | -6.92% |
| 2018 FY | 51.95 Billion KRW | 5.62% |
| 2018 Q4 | 12.92 Billion KRW | 1.5% |
| 2018 Q3 | 12.73 Billion KRW | -5.54% |
| 2018 Q2 | 13.48 Billion KRW | 5.18% |
| 2017 Q4 | 13.76 Billion KRW | 13.69% |
| 2017 FY | 49.19 Billion KRW | 3.15% |
| 2017 Q2 | 11.79 Billion KRW | 2.46% |
| 2017 Q1 | 11.51 Billion KRW | -8.51% |
| 2017 Q3 | 12.11 Billion KRW | 2.65% |
| 2016 Q4 | 12.58 Billion KRW | 6.55% |
| 2016 Q3 | 11.81 Billion KRW | -5.26% |
| 2016 Q2 | 12.46 Billion KRW | 15.15% |
| 2016 Q1 | 10.82 Billion KRW | -5.82% |
| 2016 FY | 47.69 Billion KRW | 1.11% |
| 2015 Q4 | 11.49 Billion KRW | 5.89% |
| 2015 FY | 47.16 Billion KRW | 12.72% |
| 2015 Q2 | 11.62 Billion KRW | -11.8% |
| 2015 Q3 | 10.85 Billion KRW | -6.64% |
| 2015 Q1 | 13.18 Billion KRW | 15.42% |
| 2014 Q3 | 10 Billion KRW | -4.33% |
| 2014 FY | 41.84 Billion KRW | 11.62% |
| 2014 Q4 | 11.42 Billion KRW | 14.22% |
| 2014 Q2 | 10.45 Billion KRW | 4.88% |
| 2014 Q1 | 9.96 Billion KRW | 2.26% |
| 2013 Q2 | 9.6 Billion KRW | 7.58% |
| 2013 Q1 | 8.93 Billion KRW | -9.91% |
| 2013 FY | 37.48 Billion KRW | 5.34% |
| 2013 Q4 | 9.74 Billion KRW | 5.95% |
| 2013 Q3 | 9.19 Billion KRW | -4.26% |
| 2012 Q1 | 8.27 Billion KRW | -9.13% |
| 2012 Q2 | 8.48 Billion KRW | 2.54% |
| 2012 Q3 | 8.92 Billion KRW | 5.16% |
| 2012 FY | 35.58 Billion KRW | -1.37% |
| 2012 Q4 | 9.91 Billion KRW | 11.12% |
| 2011 FY | 36.08 Billion KRW | 3.42% |
| 2011 Q2 | 8.93 Billion KRW | -0.48% |
| 2011 Q4 | 9.1 Billion KRW | 1.43% |
| 2011 Q1 | 8.97 Billion KRW | -12.84% |
| 2011 Q3 | 8.97 Billion KRW | 0.53% |
| 2010 Q2 | 7.51 Billion KRW | -17.07% |
| 2010 FY | 34.88 Billion KRW | 2.01% |
| 2010 Q4 | 10.29 Billion KRW | 28.57% |
| 2010 Q3 | 8 Billion KRW | 6.49% |
| 2010 Q1 | 9.06 Billion KRW | 2.82% |
| 2009 Q1 | 9.1 Billion KRW | -2.83% |
| 2009 FY | 34.2 Billion KRW | -0.01% |
| 2009 Q3 | 7.39 Billion KRW | -18.15% |
| 2009 Q2 | 9.03 Billion KRW | -0.79% |
| 2009 Q4 | 8.81 Billion KRW | 19.27% |
| 2008 FY | 34.2 Billion KRW | 9.97% |
| 2008 Q1 | 7.64 Billion KRW | -12.33% |
| 2008 Q2 | 8.24 Billion KRW | 7.91% |
| 2008 Q3 | 8.94 Billion KRW | 8.46% |
| 2008 Q4 | 9.37 Billion KRW | 4.77% |
| 2007 Q4 | 8.71 Billion KRW | 15.65% |
| 2007 Q1 | 6.99 Billion KRW | 0.0% |
| 2007 Q2 | 7.99 Billion KRW | 14.32% |
| 2007 FY | 31.1 Billion KRW | 0.0% |
| 2007 Q3 | 7.53 Billion KRW | -5.7% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 59.775% |
| Yuhan Corporation | 489.94 Billion KRW | 86.444% |
| Yuhan Corporation | 489.94 Billion KRW | 86.444% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -40.554% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -40.554% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -40.554% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 76.147% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -1.013% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 77.712% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 72.2% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 72.2% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 72.2% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -58.933% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 81.062% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -65.823% |
| HANDOK Inc. | 153.76 Billion KRW | 56.807% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 65.705% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | 4.04% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | 24.131% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -13.255% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -56.38% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 70.082% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | 4.392% |
| Boryung Corporation | 285.16 Billion KRW | 76.709% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | 2.772% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 47.452% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 61.862% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 61.862% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -18.535% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 73.339% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | 7.732% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | 29.004% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 47.977% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 47.977% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 43.816% |
| CKD Bio Corp. | 25.19 Billion KRW | -163.605% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 88.149% |
| JW Holdings Corporation | 301.25 Billion KRW | 77.953% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | 11.502% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 89.129% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 78.363% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 83.747% |
| JW Lifescience Corporation | 20.26 Billion KRW | -227.8% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 74.548% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 62.031% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 42.107% |